Dr. Janjigian Discusses MSI Testing in Gastric Cancer

Yelena Y. Janjigian, MD
Published: Tuesday, Sep 19, 2017



Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Though MSI-high is a relatively rare subset of gastric cancer, it is very important to distinguish these patients, says Janjigian.

MSI status must be routinely tested, Janjigian adds, because even if patients do not meet MSI criteria, a higher mutational burden may increase their chances of responding to therapy.
 


Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Though MSI-high is a relatively rare subset of gastric cancer, it is very important to distinguish these patients, says Janjigian.

MSI status must be routinely tested, Janjigian adds, because even if patients do not meet MSI criteria, a higher mutational burden may increase their chances of responding to therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
Publication Bottom Border
Border Publication
x